ライフサイエンスコーパス: lisinopril

1 so, whereas it was equivalent to those given lisinopril.

2 ice given anti-TGFbeta1 or the ACE inhibitor lisinopril.

3 -lisinopril, respectively, versus 1.9 nM for lisinopril.

4 ys of treatment with placebo, amlodipine, or lisinopril.

5 with and without pretreatment with unlabeled lisinopril.

6 e incidence of new-onset HFPEF compared with lisinopril.

7 : D(C4)lisinopril, D(C5)lisinopril, and D(C8)lisinopril.

8 tion: Treatment with sacubitril-valsartan or lisinopril.

9 in vitro with FBL, with and without 10(-6) M lisinopril.

10 those given chlorthalidone, amlodipine, and lisinopril.

11 assignment to chlorthalidone, amlodipine, or lisinopril.

12 s higher in the amlodipine (2.5-10 mg/d) and lisinopril (10-40 mg/d) arms compared with the chlorthal

13 ice were treated with Agt-ASO (66 mg/kg/wk), lisinopril (100 mg/kg/d), PBS (control), or scrambled AS

14 .5 mm Hg) than with amlodipine (-3.8 mm Hg), lisinopril (-2.4 mm Hg), or doxazosin (-3.8 mm Hg).

15 months after the creation, the ACE inhibitor lisinopril 20 mg was given orally daily.

16 inine ratio > or =300 mg/g) who all received lisinopril (80 mg once daily).

17 positron emission tomography in 17 patients (lisinopril: 9 patients, losartan: 8 patients) with hyper

18 Conversely, atenolol, when added to lisinopril, achieved maximum hemodynamic benefit and als

19 Lisinopril also decreased progression by two or more gra

20 ining the biodistribution of the 99mTc-[D(C8)lisinopril] analog in rats with and without pretreatment

21 roups to produce di(2-pyridylmethyl)amine(Cx)lisinopril analogs: D(C4)lisinopril, D(C5)lisinopril, an

22 t one level in 21 (13.2%) of 159 patients on lisinopril and 39 (23.4%) of 166 patients on placebo (od

23 dest BP changes and decreased adherence with lisinopril and absence of lipid differences with pravast

24 an ACE inhibitor (lisinopril) and placebo or lisinopril and an ARB (telmisartan), with the doses adju

25 oth cystic and noncystic cells compared with lisinopril and control treatments.

26 een designed with potency similar to that of lisinopril and has been demonstrated to specifically loc

27 Early lowering of blood pressure with lisinopril and labetalol after acute stroke seems to be

28 R) before and after long-term treatment with lisinopril and losartan in patients with hypertension an

29 The angiotensin converting enzyme inhibitor lisinopril and mineralocorticoid receptor (MR) antagonis

30 values ranging from 44 to 4500 nM for Ni-NTA-lisinopril and Ni-DOTA-lisinopril, respectively, versus

31 Early treatment with heart failure drugs lisinopril and spironolactone improves skeletal muscle p

32 In early ADPKD, the combination of lisinopril and telmisartan did not significantly alter t

33 three months of MR and decreased during both lisinopril and the combined therapy in which it was not

34 y-surface area) to receive an ACE inhibitor (lisinopril) and placebo or lisinopril and an ARB (telmis

35 (2) 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and 12.5 mg hydrochlorothiazide or to usual

36 (1) 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and 50 mg atenolol or (2) 75 mg aspirin, 40

37 hydroxy-beta-methylbutyrate, trichostatin A, lisinopril, and 6 from the glucocorticoid family) signif

38 isease, was identical in the chlorthalidone, lisinopril, and amlodipine groups.

39 nt of the relative effect of chlorthalidone, lisinopril, and amlodipine in preventing HF.

40 Cx)lisinopril analogs: D(C4)lisinopril, D(C5)lisinopril, and D(C8)lisinopril.

41 opril (EDTA-lisinopril, NTA-lisinopril, DOTA-lisinopril, and GGH-lisinopril) conjugates were used to

42 Labetalol and lisinopril are effective antihypertensive drugs in acute

43 ese results indicate that both diltiazem and lisinopril are safe for treatment of hypertension after

44 a and then randomly assigned them to receive lisinopril (at a dose of 10 to 40 mg per day) or placebo

45 n-induced LVH after long-term treatment with lisinopril but not with losartan.

46 GGH were linked to the lysine side chain of lisinopril by 1-ethyl-3-[3-(dimethylamino)propyl]carbodi

47 (M = technetium, rhenium) was conjugated to lisinopril by acylation of the epsilon-amine of the lysi

48 0.89-1.25), respectively, for amlodipine and lisinopril compared with chlorthalidone, and 10-year adj

49 This class of metal chelate-lisinopril complexes possesses a range of high-affinity

50 dent inactivation of sACE-1 by metal chelate-lisinopril complexes revealed a remarkable range of cata

51 endent inhibition of sACE-1 by metal chelate-lisinopril complexes revealed IC(50) values ranging from

52 ting a more optimal orientation of M-chelate-lisinopril complexes within the active site of the N-dom

53 , following preincubation with metal chelate-lisinopril compounds.

54 il, NTA-lisinopril, DOTA-lisinopril, and GGH-lisinopril) conjugates were used to form coordination co

55 where the distance of the chelator from the lisinopril core was investigated by varying the number o

56 nar anterior imaging analysis of 99mTc-[D(C8)lisinopril] corroborated these data.

57 bacute hemodynamic effects of amlodipine and lisinopril could contribute to the differences in CCA re

58 iron, cobalt, nickel, and copper, such that lisinopril could mediate localization of the reactive me

59 Herein, the activity of lisinopril-coupled transition metal chelates was tested

60 idylmethyl)amine(Cx)lisinopril analogs: D(C4)lisinopril, D(C5)lisinopril, and D(C8)lisinopril.

61 d time-averaged WSS in the CCA compared with lisinopril, despite similar reductions in BP.

62 ked chelate-lisinopril (EDTA-lisinopril, NTA-lisinopril, DOTA-lisinopril, and GGH-lisinopril) conjuga

63 The resulting amide-linked chelate-lisinopril (EDTA-lisinopril, NTA-lisinopril, DOTA-lisino

64 ted the effects found in rats medicated with lisinopril, except that cardiac ACE2 mRNA fell to values

65 A new radiotracer, 18F-fluorobenzoyl-lisinopril (FBL), was synthesized without compromising i

66 ith different concentrations of captopril or lisinopril for 5 days.

67 rapy, the beta-blocker atenolol was added to lisinopril for another three months.

68 the effectiveness and safety of diltiazem or lisinopril for treatment of hypertension after heart tra

69 o 35 mg daily, n=1568) of the ACE inhibitor, lisinopril, for 39 to 58 months, while background therap

70 7) in the placebo group and 59% (103) in the lisinopril group (p = 0.2).

71 t maximal coronary blood flow and MPR in the lisinopril group increased significantly compared with p

72 Patients on lisinopril had significantly lower HbA1c at baseline tha

73 with chlorthalidone, randomization to either lisinopril (hazard ratio, 1.04; 95% confidence interval,

74 e had significantly lower risk than those on lisinopril (HR, 1.18 versus 2.57; P=0.04 for interaction

75 rophic mice treated with spironolactone plus lisinopril (IC50 0.1 nM) compared with untreated control

76 sinopril], IC50 = 1,146 nM, as compared with lisinopril, IC50 = 4 nM.

77 D(C5)lisinopril], IC50 = 144 nM; and Re[D(C4)lisinopril], IC50 = 1,146 nM, as compared with lisinopri

78 concentration of 50% (IC50) = 3 nM; Re[D(C5)lisinopril], IC50 = 144 nM; and Re[D(C4)lisinopril], IC5

79 inhibits angiotensinogen (Agt) synthesis to lisinopril in adult conditional Pkd1 systemic-knockout m

80 the effectiveness and safety of diltiazem or lisinopril in the treatment of hypertension in cyclospor

81 nce and absence of the antihypertensive drug lisinopril) in order to aid the understanding of how the

82 Losartan treatment but not lisinopril increased cardiac tissue levels of Ang II and

83 the length of the methylene spacer: Re[D(C8)lisinopril], inhibitory concentration of 50% (IC50) = 3

84 Compared with chlorthalidone, treatment with lisinopril is not associated with a meaningful reduction

85 Neither amlodipine nor lisinopril is superior to chlorthalidone in preventing C

86 after continuous administration of vehicle, lisinopril, losartan, or both drugs combined in their dr

87 Amlodipine and lisinopril lowered BP similarly, but CCA flow rate was s

88 Lisinopril may decrease retinopathy progression in non-h

89 ndomly assigned to receive labetolol (n=58), lisinopril (n=58), or placebo (n=63) between January, 20

90 an angiotensin-converting enzyme inhibitor (lisinopril; n = 8233), or an alpha-blocker (doxazosin; n

91 with one of the most widely used inhibitors, lisinopril (N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-

92 ulting amide-linked chelate-lisinopril (EDTA-lisinopril, NTA-lisinopril, DOTA-lisinopril, and GGH-lis

93 We investigated the effect of lisinopril on retinopathy in type 1 diabetes.

94 ACE2 is not inhibited by lisinopril or captopril.

95 d showed reduced cystic volume compared with lisinopril or control treatments.

96 n blood pressure were obtained in rats given lisinopril or losartan alone or in combination.

97 alidone, 5.6% with amlodipine, and 4.3% with lisinopril), or no diabetes at 2 years of in-trial follo

98 h the angiotensin converting enzyme blocker, lisinopril, or angiotensin II receptor blocker, losartan

99 ere randomly assigned to receive amlodipine, lisinopril, or chlorthalidone.

100 ts randomized to chlorthalidone, amlodipine, lisinopril, or doxazosin treatments and followed up for

101 ) determined that treatment with amlodipine, lisinopril, or doxazosin was not superior to thiazide-li

102 re randomized to chlorthalidone, amlodipine, lisinopril, or doxazosin, providing an opportunity to co

103 the risk of HFPEF compared with amlodipine, lisinopril, or doxazosin; the hazard ratios were 0.69 (9

104 classical ACE inhibitors such as captopril, lisinopril, or enalaprilat.

105 phagic, or intravenous labetalol, sublingual lisinopril, or placebo if they had dysphagia, within 36

106 ral randomisation to receive oral labetalol, lisinopril, or placebo if they were non-dysphagic, or in

107 ubated in solution containing cold, 10(-6) M lisinopril (P < 0.0001).

108 omized and 34 [lisinopril/pravastatin (n=9), lisinopril/P-placebo (n=8), L-placebo/pravastatin (n=9),

109 emia with rosiglitazone or hypertension with lisinopril partially reduced ACR, consistent with indepe

110 een the lisinopril-telmisartan group and the lisinopril-placebo group.

111 ngiotensin-receptor blocker (telmisartan) or lisinopril plus placebo.

112 an angiotensin-converting-enzyme inhibitor (lisinopril) plus an angiotensin-receptor blocker (telmis

113 y-seven participants were randomized and 34 [lisinopril/pravastatin (n=9), lisinopril/P-placebo (n=8)

114 sought to determine whether randomization to lisinopril reduces incident AF or atrial flutter (AFL) c

115 to 4500 nM for Ni-NTA-lisinopril and Ni-DOTA-lisinopril, respectively, versus 1.9 nM for lisinopril.

116 utralization of TGFbeta1 by anti-TGFbeta1 or lisinopril resulted in less collagen deposition and less

117 Similarly, captopril and lisinopril significantly inhibited intracellular accumul

118 Although lisinopril significantly reduced preload, its effect on

119 One het group received spironolactone and lisinopril starting at 8 weeks of life (het-treated-8);

120 as dramatically reduced by pretreatment with lisinopril, supporting ACE-mediated binding in vivo.

121 without significant differences between the lisinopril-telmisartan group and the lisinopril-placebo

122 composite primary outcome (hazard ratio with lisinopril-telmisartan, 1.08; 95% confidence interval, 0

123 Blood pressure was better controlled with lisinopril than with Agt-ASO.

124 After three months of lisinopril therapy, the beta-blocker atenolol was added

125 so reduced in thyroids of anti-TGFbeta1- and lisinopril-treated mice compared with those of controls.

126 Of 61 lisinopril-treated patients, 28 (46%) were responders, 2

127 from 100 +/- 1.0 to 84 +/- 2.0 mm Hg in the lisinopril-treated responders (p < 0.0001).

128 from 153 +/- 2.1 to 127 +/- 2.7 mm Hg in the lisinopril-treated responders (p < 0.0001).

129 months of MR and rose insignificantly after lisinopril treatment (2.99 +/- 0.17).

130 all of the CCA was significantly lower after lisinopril treatment than after amlodipine treatment (P

131 .016) after amlodipine treatment than after lisinopril treatment.

132 sed with chlorthalidone versus amlodipine or lisinopril use during year 1.

133 model showed relative risks of amlodipine or lisinopril versus chlorthalidone during year 1 were 2.22

134 idence intervals; P values) of amlodipine or lisinopril versus chlorthalidone were 1.35 (1.21 to 1.50

135 Participants taking lisinopril vs L-placebo were more likely to report misse

136 Participants randomized to lisinopril vs. L-placebo had significant declines in dia

137 A single dose of lisinopril was administered during study days to ensure

138 ity, whereas the combination of losartan and lisinopril was associated with elevated cardiac ACE2 act

139 hyperemic flow in the patients treated with lisinopril was not significantly different from correspo

140 Lisinopril was similar to chlorthalidone in preventing C

141 nts as high as 150,000 M(-1) min(-1) (Cu-GGH-lisinopril), while catalyst-mediated cleavage of sACE-1

142 .77-1.42) than participants on amlodipine or lisinopril with incident diabetes (HR range, 1.22-1.53).

143 Chlorthalidone was similar to lisinopril with regard to incidence of HFREF (hazard rat

144 % of participants (chlorthalidone/amlodipine/lisinopril) with new-onset HFPEF versus 41.9% in those w